Combination therapy with targeted 4-1bb (cd137) agonists
AssigneeHoffmann-La Roche Inc.
InventorsMarina BACAC, Christina CLAUS, Claudia FERRARA KOLLER, Christian KLEIN, Sabine LANG, Viktor LEVITSKI, Pablo UMAÑA
Life of this patent
Estimating the term…
Abstract
The present invention relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and/or agents blocking PD-L1/PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
Claims12
-50. (canceled)
A method for treating or delaying progression of cancer in a subject, wherein the method comprises administering to the subject an effective amount of a T-cell activating anti-carcinoembryonic antigen (CEA)/anti-CD3 bispecific antibody and an effective amount of a 4-1BB agonist comprising at least one antigen binding domain capable of specific binding to fibroblast activation protein (FAP).
The method of claim 67, wherein the 4-1BB agonist comprising at least one antigen binding domain capable of specific binding to FAP comprises three ectodomains of 4-1BBL or fragments thereof.
The method of claim 67, wherein the T-cell activating anti-CEA/anti-CD3 bispecific antibody comprises a first antigen binding domain comprising a heavy chain variable region (VHCD3) and a light chain variable region (VLCD3);
- and a second antigen binding domain comprising a heavy chain variable region (VHCEA) and a light chain variable region (VLCEA).
Dependencies are inferred from the claim text.